Emyria's Expansion of Authorised Prescriber Team for MDMA-Assisted Therapy

Emyria Limited (ASX: $EMD) has announced the approval of its second psychiatrist as an 'Authorised Prescriber' (AP) for MDMA-assisted therapy for PTSD by the Therapeutic Goods Administration (TGA). This significant milestone reflects Emyria's commitment to broadening mental health care treatment options within the stringent regulatory and ethical frameworks mandated by the TGA.

Executive Commentary on Expanding Authorised Prescriber Team

Dr. Michael Winlo, CEO, expressed, 'Our second authorisation demonstrates Emyria's commitment and ability to increase our service capacity to evaluate emerging treatments for mental health within the strict regulatory frameworks established by the TGA. Our initial focus is on evaluating MDMA-assisted therapy for PTSD. With the female incidence of PTSD almost twice that of males, we are pleased to support an approach that acknowledges and addresses the specific needs of women suffering from PTSD by supporting the first approved female Authorised Prescriber for MDMA-AT. We are excited to be building a unique company that is both directly helping patients today, while also applying its revenue and unique data insights to support a long-term innovation agenda.'

Summary of Emyria's Expansion and Future Outlook

Emyria's recent announcement of the approval of its second psychiatrist as an 'Authorised Prescriber' for MDMA-assisted therapy signifies a significant step in the company's dedication to expanding mental health care treatment options. With a focus on evaluating MDMA-assisted therapy for PTSD, Emyria aims to address the specific needs of women suffering from PTSD by supporting the first approved female Authorised Prescriber for MDMA-AT. The company's long-term innovation pipeline includes efforts to support proprietary innovation and develop new care models and novel drug treatments. Emyria's ambitions to become a comprehensive provider of specialist-led, legal, psychedelic-assisted therapies and its exploration of a scalable commercialisation strategy demonstrate its commitment to improving access to new treatments for patients in need.